Hindawi出版/Blog/Blog Post

从我们最新的期刊

与双提交和公布处理

作者| Research integrity
与双提交和公布处理

This post addresses some of the issues surrounding dual publication and dual submission. Why is it a problem? How does it happen? And most importantly, what are the alternatives?


o期刊通常只允许一个正式版本f each paper, to ensure that research articles are a useful record of academic work. To avoid such dual publication from happening, most publishers disallow dual submission and ask you to send each manuscript to one journal at a time.

The problem with dual publication

当相同的文章出现在不同的期刊,这引入了一系列的问题。首先,作者的发表记录现在包括误导性信息。他们的一个文件被视为两个独立的文件,它不会很清楚其他研究者哪个版本是引用的首选版本。

当有人运行公开发表的文献进行了荟萃分析,包括相同的实验结果两次出现在两个独立的出版物他们的结果会出现更严重的问题。这overrepresents特定部分在系统评价的分析数据,这可能对病人的治疗和进一步研究的后果。

还有的期刊以及影响。例如,具有预先发表的论文出现在第二杂志可以是侵犯版权的,如果作者已经签署了的权利,第一个杂志。另一个问题是,文章的一次双出版物被捕获至少一个通常需要被收回。该博客回缩腕表拥有reported on一些发生一举两得公布的结果,撤消的。这些撤稿并不总是形容当相同的手稿被送往两个不同的地方,相同的结果包括在不同的手稿,或论文在不同的语言提交给不同的期刊的情况下,也病例。

避免双重意见书

为了避免双重出版,很多期刊已经制定了指导方针,以阻止双提交 -including Hindawi’s. This started in 1969, when Franz Ingelfinger wrote a policy for the New England Journal of Medicine stating that the journal would only accept submissions that had not been submitted or published elsewhere. Since then, many other journals have also adopted this “Ingelfinger Rule”.

尽管这一政策,双重提交还是发生了。他们经常会用谁被分配到手稿在两个期刊,或者通过抄袭检测软件评审或编辑捕获。当时间通知,编辑将拒绝该稿件,并提醒对双重提交政策的作者,甚至告知作者的机构,但有时这些事件可能更为复杂和出版委员会伦理委员会(COPE)曾就一些of these situations.

Just like dual publication, dual submissions take up publisher time and resources that could have been used to work on other manuscripts. Editors and reviewers at one of the journals will have wasted time working on an article they can never publish. In these simultaneous submissions authors also often ignore critical reviewer comments from journals they don’t end up publishing with.

在许多情况下,研究人员可能不知道,这是不恰当的发送同样的文稿出多个分身,尤其是如果这是他们的第一篇论文。也许他们希望能加快发布过程,并尽快弄到一张纸出来。或者,他们两面下注,希望能够在自己喜爱的杂志上得到接受出版,尽管他们知道,该文件是一个更适合的其他地方。或者,也许他们认为发出不同语言的同一稿件会得到他们的工作更多的人注意到,或者没有意识到,他们不能包含两种不同的,否则试卷相同的结果。

想要更快的发布,达到国际观众或指用于不同的研究相同的数据都是有效的关注,但解决的办法是不提交到多个刊物上一次。相反,有一些方法来处理所有的这些挑战。

Alternatives to dual submissions

许多出版商现在允许你提交的文稿存入一个预印本服务器。这个版本没有经过同行评议过去了,还没有被出版社编辑或格式化。但它确实让你与世界分享你的文件,只要你准备好提交。即使需要一年,最终得到了同行评议的版本出版,即使你想试试你的手气,更有选择性的日记,你的同事将已经能够读取原稿。

预印本是在研究比其他某些地区更为普遍。自1991年以来该预印本服务器的arXiv一直是数学和物理学社会的中流砥柱,但现在其他领域正在迅速追赶。对于一些出版商来说,采用预印本意味着提炼他们的双出版政策的语言,因为原来Ingelfinger规则似乎劝阻它(当然,把它写在这样一个时代很久之前网上公布了规范)。

Now, many policies specifically state that they will still consider a manuscript for publication if the authors have uploaded an unreviewed preprint, just like they would allow you to publish a paper after you’ve given a conference talk about the topic. To find out the preprint policy of a particular publication check theSHERPA / ROMEO数据库,其中列出了出版商和期刊政策对自存档的手稿。

When you’re working on two different manuscripts that use the same dataset, or if you would like your article to be available in different languages, always let the editors know about your plans, and they can help you find a way to achieve these goals. Sometimes the solution is to publish a paper together with a translation, or to publish two closely related papers back-to-back. The International Committee of Medical Journal Editors (ICMJE) has a标准清单的情况下二次出版物可以接受他们的第一个点是得到编辑的批准。

Ultimately, there’s no need to send out the same manuscript to multiple journals at once. It’s against most publishers’ policies and will only cause delays or even retractions. The best thing to do is to be transparent when communicating with your editors, post a preprint when you can, and make sure that your colleagues are all aware of policies preventing dual submission and publication.


This blog post is distributed under theCreative Commons Attribution License (CC-BY). Views and opinions expressed are those of the author and do not necessarily represent the views of Hindawi. The illustration is by Hindawi and is also CC-BY.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us athelp@hindawi.com以确保他们的研究是快速跟踪和尽快预印本服务器上公布。我们将针对与COVID-19接受的文章中提供的出版费用减免无限。Sign up here作为一个评论家,以帮助快速跟踪新的意见书。